NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human ...
The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...
Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the ...
Corbus Pharmaceuticals has a 52 week low of $9.11 and a 52 week high of $61.90. The stock has a market cap of $119.11 million, a P/E ratio of -2.09 and a beta of 2.63. Institutional Inflows and ...
Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $26.68. Corbus ...
Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...
In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback